{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:41:20Z","timestamp":1791157280449,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006017","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2008,4,23]],"date-time":"2008-04-23T00:00:00Z","timestamp":1208908800000}}],"reference-count":201,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006017.pub2","type":"journal-article","created":{"date-parts":[[2008,4,21]],"date-time":"2008-04-21T09:56:47Z","timestamp":1208771807000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Targeted therapy for advanced renal cell carcinoma"],"prefix":"10.1002","volume":"2011","author":[{"given":"Chris","family":"Coppin","sequence":"first","affiliation":[{"name":"British Columbia Cancer Agency, Vancouver Centre; 600 West 10th Avenue Vancouver British Columbia Canada V5Z 4E6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyly","family":"Le","sequence":"additional","affiliation":[{"name":"British Columbia Cancer Agency; Fraser Valley Cancer Centre; 13750 - 96th Avenue Surrey BC Canada V3V 1Z2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J","family":"Wilt","sequence":"additional","affiliation":[{"name":"VAMC; General Internal Medicine (111-0); One Veterans Drive Minneapolis Minnesota USA 55417"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kollmannsberger","sequence":"additional","affiliation":[{"name":"British Columbia Cancer Agency, Vancouver Centre; 600 West 10th Avenue Vancouver British Columbia Canada V5Z 4E6"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,4,23]]},"reference":[{"key":"10.1002\/14651858.CD006017.pub2-BIB0001|cit1","unstructured":"Atkins MB Hidalgo M Stadler W A randomized double-blind phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2002 abstr 36"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0003|cit3","unstructured":"Hidalgo M Atkins MB Stadler W A randomized double-blind phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma: prognostic factor analysis Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2003 abstr 804"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0004|cit4","unstructured":"see Atkins 2004"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0005|cit5","unstructured":"see Atkins 2004"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0006|cit6","unstructured":"see Atkins 2004"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Bhargava P Esteves B Al-Adhami M Activity of Tivozanib (AV-951) in patients with renal cell carcinoma: subgroup analysis from a phase II randomized discontinuation trial Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2010 abstr 4599","DOI":"10.1200\/jco.2010.28.15_suppl.4599"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0008|cit8","unstructured":"Bhargava P Esteves B Al-Adhami M Effect of hypertension, nephrectomy, and prior treatment on the efficacy of tivozanib (AV-951) in a phase II discontinuation trial in patients with renal cell carcinoma Genitourinary Cancers Symposium, American Society of Clinical Oncology 2010 abstr 342"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0009|cit9","unstructured":"Bhargava P Esteves B Lipatov ON Activity and safety of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma: interim results of a phase II randomized discontinuation trial Genitourinary Cancers Symposium, American Society of Clinical Oncology 2009 abstr 283"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Bhargava P Esteves B Nosov DA Lipatov ON Updated activity and safety results of a phase II randomized discontinuation trial of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2009 abstr 5032","DOI":"10.1200\/jco.2009.27.15_suppl.5032"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0011|cit11","doi-asserted-by":"crossref","unstructured":"Bracarda S Ludovini V Porta C Serum thrombospondin, vascular endothelial growth factor, VEGF receptor-2, and basic-fibroblast growth factor as predictive factors for sorafenib plus interferon-alfa-2a in metastatic renal cell carcinoma: biologic results from the randomized phase II RAPSODY trial Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2010 abstr 4628","DOI":"10.1200\/jco.2010.28.15_suppl.4628"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"Bracarda S Porta C Boni C Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-a2a in metastatic renal cell carcinoma (RAPSODY): GOIRC Study 0681 Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2007 abstr 5100","DOI":"10.1200\/jco.2007.25.18_suppl.5100"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0013|cit13","doi-asserted-by":"crossref","unstructured":"Bracarda S Porta C Boni C Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-a2a in metastatic renal cell carcinoma (RAPSODY): GOIRC study 0681 Genitourinary Cancers Symposium, American Society of Clinical Oncology 2008 abstr 357","DOI":"10.1200\/jco.2007.25.18_suppl.5100"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0014|cit14","doi-asserted-by":"crossref","unstructured":"Bukowski RM Kabbinavar F Figlin RA Bevacizumab with or without erlotinib in metastatic renal cell carcinoma Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2006 abstr 4523","DOI":"10.1200\/jco.2006.24.18_suppl.4523"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0015|cit15","unstructured":"Bukowski RM Kabbinavar F Figlin RA Bevacizumab with or without erlotinib in metastatic renal cell carcinoma http:\/\/www.asco.org\/ASCOv2\/Meetings\/Abstracts?&vmview=abst_detail_view&confID=40&abstractID=33238 [accessed 10 January 2007] 2006"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2007.11.5154","article-title":"Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer","volume":"25","author":"Bukowski","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"6689","DOI":"10.1158\/1078-0432.CCR-07-1477","article-title":"Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma","volume":"13","author":"Ebbinghaus","year":"2007","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0018|cit18","doi-asserted-by":"crossref","unstructured":"Ebbinghaus SW Hussain M Tannir NM A randomized phase II study of the thrombospondin-mimetic peptide ABT-510 in patients with previously untreated advanced renal cell carcinoma Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2005 abstr 4607","DOI":"10.1200\/jco.2005.23.16_suppl.4607"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.juro.2007.07.035","article-title":"Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941","volume":"178","author":"Escudier","year":"2007","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0020|cit20","doi-asserted-by":"crossref","unstructured":"Escudier B Venner P Buckowski R Phase III trial of Neovastat in metastatic renal cell carcinoma patients refractory to immunotherapy Journal of Oncology, ASCO Annual Meeting Proceedings 2003 abstr 844","DOI":"10.1016\/S1359-6349(03)91124-4"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0021|cit21","doi-asserted-by":"crossref","unstructured":"Escudier B Venner P Bukowski R Phase III trial of Neovastat in metastatic renal cell carcinoma patients refractory to immunotherapy European Journal of Cancer Supplements, ECCO 12 Meeting Proceedings 2003 abstr 1098","DOI":"10.1016\/S1359-6349(03)91124-4"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0022|cit22","first-page":"136","article-title":"Cartilage in therapy of renal cell cancer","volume":"9","author":"Nurzynski","year":"2005","journal-title":"Wspolczesna Onkologia"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1200\/JCO.2009.24.9730","article-title":"Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study","volume":"28","author":"Antoun","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/01.coc.0000258732.80710.05","article-title":"Effects of sorafenib on symptoms and quality of life. Results from a large randomized placebo-controlled study in renal cancer","volume":"30","author":"Bukowski","year":"2007","journal-title":"American Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0025|cit25","doi-asserted-by":"crossref","unstructured":"Bukowski R Eisen TE Stadler WS Efficacy and safety of sorafenib in patients with advanced clear-cell renal-cell carcinoma with bone metastases: results from the phase III target study European Journal of Cancer Supplements, ECCO 15 Meeting Proceedings 2009 abstr 7130","DOI":"10.1016\/S1359-6349(09)71463-6"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0026|cit26","doi-asserted-by":"crossref","unstructured":"Bukowski RM Eisen T Szczylik C Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2007 abstr 5023","DOI":"10.1200\/jco.2007.25.18_suppl.5023"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0027|cit27","doi-asserted-by":"crossref","unstructured":"Bukowski RM Eisen T Szczylik C Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis www.asco.org\/virtual meeting [accessed 10 January 2007] 2007","DOI":"10.1200\/jco.2007.25.18_suppl.5023"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0028|cit28","doi-asserted-by":"crossref","unstructured":"Dhanda R Gondek K Song J A quality of life, symptoms and survival comparison in kidney cancer patients receiving sorafenib versus placebo Annals of Oncology, ESMO Meeting Proceedings 2006 abstr 447PD","DOI":"10.1200\/jco.2006.24.18_suppl.4534"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0029|cit29","doi-asserted-by":"crossref","unstructured":"Eisen T Bukowski RM Staehler M Randomized phase III trial of sorafenib in advanced renal cell carcinoma: impact of crossover on survival Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2006 abstr 4524","DOI":"10.1200\/jco.2006.24.18_suppl.4524"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0030|cit30","unstructured":"Eisen T Oudard S Szczylik C Clinical benefit of sorafenib in the elderly with advanced renal cell carcinoma: subgroup analysis of the approaches in renal cancer global evaluation trial (TARGETs) Annals of Oncology, ESMO Meeting Proceedings 2006 abstr 446PD"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/jnci\/djn319","article-title":"Sorafenib for older patients with renal cell carcinomas: subset analysis from a randomized trial","volume":"100","author":"Eisen","year":"2008","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","article-title":"Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III Treatment Approaches in Renal cancer Global Evaluation Trial","volume":"27","author":"Escudier","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0034|cit34","unstructured":"Massard C Zonierek J Laplanche A Incidence of brain metastasis in advanced renal cell carcinoma among patients randomized in a phase III trial of sorafenib, an oral multi-kinase inhibitor Annals of Oncology, ESMO Meeting Proceedings 2006 abstr 454P"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0035|cit35","unstructured":"Negrier S Jager E Port C Sorafenib in patients with advanced renal cell carcinoma and prior cytokine therapy: subgroup analysis of TARGETs Annals of Oncology, ESMO Meeting Proceedings 2006 abstr 4390"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0036|cit36","doi-asserted-by":"crossref","unstructured":"Bajetta E Ravaud A Bracarda S Efficacy and safety of first-line bevacizumab plus interferon-a2a in patients \u2265 65 years with metastatic renal cell carcinoma Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2007 abstr 5095","DOI":"10.1200\/jco.2008.26.15_suppl.5095"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0037|cit37","doi-asserted-by":"crossref","unstructured":"Bellmunt J Melichar B Bracarda S Bevacizumab and interferon therapy does not increase risk of cardiac events in metastatic renal cell carcinoma European Journal of Cancer Supplements, ECCO 15 Meeting Proceedings 2009 abstr 7121","DOI":"10.1016\/S1359-6349(09)71454-5"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0038|cit38","doi-asserted-by":"crossref","unstructured":"Bracarda S Bellmunt J Negrier SN What is the impact of subsequent anti-neoplastic therapy on overall survival following first-line bevacizumab\/interferon-alpha2a in metastatic renal cell carcinoma - experience from AVOREN European Journal of Cancer Supplements, ECCO 15 Meeting Proceedings 2009 abstr 7127","DOI":"10.1016\/S1359-6349(09)71459-4"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0039|cit39","doi-asserted-by":"crossref","unstructured":"Bracarda S Koralewski P Pluzanska A Bevacizumab\/interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN) European Journal of Cancer Supplements, ECCO 14 Meeting Proceedings 2007 abstr 4008","DOI":"10.1016\/S1359-6349(07)71076-5"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0040|cit40","doi-asserted-by":"crossref","unstructured":"Escudier B Koralewski P Pluzanska A A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab\/interferon-a2a vs placebo\/interferon-\u03b12a as first-line therapy in metastatic renal cell carcinoma Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2007 abstr 3","DOI":"10.1200\/jco.2007.25.18_suppl.3"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0041|cit41","doi-asserted-by":"crossref","unstructured":"Escudier B Koralewski P Pluzanska A A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab\/interferon-a2a vs placebo\/interferon-\u03b12a as first-line therapy in metastatic renal cell carcinoma www.asco.org\/virtual meeting [accessed 10 January 2007] 2007","DOI":"10.1200\/jco.2007.25.18_suppl.3"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","article-title":"Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival","volume":"28","author":"Escudier","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0044|cit44","doi-asserted-by":"crossref","unstructured":"Escudier BJ Bellmunt J Negrier Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab + interferon-\u03b12a in metastatic renal cell carcinoma Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2009 abstr 5020","DOI":"10.1200\/jco.2009.27.15_suppl.5020"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0045|cit45","doi-asserted-by":"crossref","unstructured":"Escudier BJ Negrier S Chevreau C Analysis of prognostic risk categories in the phase III AVOREN trial of first-line bevacizumab plus interferon-\u03b12a in patients with metastatic renal cell carcinoma: French prognostic scoring system Genitourinary Cancers Symposium, American Society of Clinical Oncology 2010 abstr 417","DOI":"10.1200\/jco.2009.27.15_suppl.5020"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0046|cit46","doi-asserted-by":"crossref","unstructured":"Escudier BJ Ravaud A Negrier S Update on AVOREN trial in metastatic renal cell carcinoma: efficacy and safety in subgroups of patients and pharmacokinetic analysis Genitourinary Cancers Symposium, American Society of Clinical Oncology 2008 abstr 5025","DOI":"10.1200\/jco.2008.26.15_suppl.5025"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0047|cit47","doi-asserted-by":"crossref","unstructured":"Karakiewicz P Sun M Sneller V Escudier B Use of a nomogram to quantify overall survival (OS) benefit in patients with metastatic renal cell carcinoma receiving bevacizumab (BEV) with interferon (IFN) versus IFN alone Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2010 suppl abstr 4592","DOI":"10.1200\/jco.2010.28.15_suppl.4592"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0048|cit48","doi-asserted-by":"crossref","unstructured":"Karakiewicz PI Sun M Sneller V Use of a nomogram to quantify progression-free survival benefit in metastatic renal cell carcinoma patients receiving bevacizumab plus interferon or interferon alone Genitourinary Cancers Symposium, American Society of Clinical Oncology 2010 abstr 392","DOI":"10.1200\/jco.2010.28.15_suppl.4592"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0049|cit49","doi-asserted-by":"crossref","unstructured":"Melichar B Koralewski P Pluzanska A First-line bevacizumab improves progression-free survival with lower doses of interferon-\u03b12a in the treatment of patients with metastatic renal cell carcinoma (AVOREN) European Journal of Cancer Supplements 2007 abstr 4518","DOI":"10.1016\/S1359-6349(07)71149-7"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/annonc\/mdn161","article-title":"First-line bevacizumab combined with reduced dose interferon-\u03b12a is active in patients with metastatic renal cell carcinoma","volume":"19","author":"Melichar","year":"2008","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0051|cit51","doi-asserted-by":"crossref","unstructured":"Escudier B Szczylik C Demkow T Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon in treatment-na\u00efve patients with metastatic renal cell carcinoma Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2006 abstr 4501","DOI":"10.1200\/jco.2006.24.18_suppl.4501"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1200\/JCO.2008.19.3342","article-title":"Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma","volume":"27","author":"Escudier","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0053|cit53","doi-asserted-by":"crossref","unstructured":"Szczylik C Demkow T Staehler M Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2007 abstr 5025","DOI":"10.1200\/jco.2007.25.18_suppl.5025"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0054|cit54","doi-asserted-by":"crossref","unstructured":"Szczylik C Demkow T Staehler M Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results www.asco.org\/virtual meeting [accessed 10 January 2007] 2007","DOI":"10.1200\/jco.2007.25.18_suppl.5025"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0055|cit55","doi-asserted-by":"crossref","unstructured":"Escudier BJ Negrier S Gravis G Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma? Results of the randomized TORAVA phase II trial Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2010 abstr 4516","DOI":"10.1200\/jco.2010.28.15_suppl.4516"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0056|cit56","doi-asserted-by":"crossref","unstructured":"Gordon MS Manola J Fairclough D Low dose interferon-\u03b12b + thalidomide in patients with previously untreated renal cell cancer. Improvement in progression-free survival but not quality of life or overall survival. A phase III study of the Eastern Cooperative Oncology Group (E2898) Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2004 abstr 4516","DOI":"10.1200\/jco.2004.22.90140.4516"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0057|cit57","doi-asserted-by":"crossref","unstructured":"Gordon MS Manola J Fairclough D Low dose interferon-\u03b12b + thalidomide in patients with previously untreated renal cell cancer. Improvement in progression-free survival but not quality of life or overall survival. A phase III study of the Eastern Cooperative Oncology Group (E2898) www.asco.org\/virtual meeting [accessed 10 January 2007] 2004","DOI":"10.1200\/jco.2004.22.90140.4516"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0058|cit58","unstructured":"Alemao E Rajagopalan S Yang S Quality adjusted survival in randomized, controlled trials: application of inverse probability weighting in renal cell cancer Genitourinary Cancers Symposium, American Society of Clinical Oncology 2010 abstr 399"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0059|cit59","doi-asserted-by":"crossref","unstructured":"Armstrong AJ George DJ Halabi S Serum lactate dehydrogenase as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2010 abstr 4631","DOI":"10.1200\/jco.2010.28.15_suppl.4631"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0060|cit60","doi-asserted-by":"crossref","unstructured":"Dutcher JP Szczylik C Tannir N Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon-alpha Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2007 abstr 5033","DOI":"10.1200\/jco.2007.25.18_suppl.5033"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0061|cit61","doi-asserted-by":"crossref","unstructured":"Dutcher JP Szczylik C Tannir N Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon-alpha www.asco.org\/virtual meeting [accessed 10 January 2007] 2007","DOI":"10.1200\/jco.2007.25.18_suppl.5033"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0062|cit62","unstructured":"Dutcher JP de Souza P Figlin R Effect of temsirolimus versus interferon-\u03b1 on survival of patients with advanced renal cell carcinoma of different histologies Genitourinary Cancers Symposium, American Society of Clinical Oncology 2008 abstr 384"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12032-009-9177-0","article-title":"Effect of temsirolimus versus interferon-\u03b1 on outcome of patients with advanced renal cell carcinoma of different histologies","volume":"26","author":"Dutcher","year":"2009","journal-title":"Medical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0064|cit64","doi-asserted-by":"crossref","unstructured":"Hudes G Carducci M Tomczak P A phase 3, randomized, 3-arm study of temsirolimus or interferon-alpha or the combination in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2006 abstr LBA4","DOI":"10.1200\/jco.2006.24.18_suppl.lba4"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0066|cit66","unstructured":"Logan T McDermott D Dutcher J Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features Genitourinary Cancers Symposium, American Society of Clinical Oncology 2009 abstr 281"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0067|cit67","doi-asserted-by":"crossref","unstructured":"Pablo M Hudes G Dutcher J Radiographic findings of drug-induced pneumonitis and clinical correlation in patients with advanced renal cell carcinoma treated with temsirolimus European Journal of Cancer Supplements, ECCO 15 Meeting Proceedings 2009 abstr 7113","DOI":"10.1016\/S1359-6349(09)71446-6"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0068|cit68","doi-asserted-by":"crossref","unstructured":"Parasuraman S Hudes G Levy D Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-\u03b1 (IFN) or the combination of IFN+TEMSR Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2007 abstr 5049","DOI":"10.1200\/jco.2007.25.18_suppl.5049"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0069|cit69","doi-asserted-by":"crossref","unstructured":"Parasuraman S Hudes G Levy D Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-\u03b1 (IFN) or the combination of IFN+TEMSR www.asco.org\/virtual meeting [accessed 15 January 2007] 2007","DOI":"10.1200\/jco.2007.25.18_suppl.5049"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0070|cit70","doi-asserted-by":"crossref","unstructured":"Yang S Hudes G de Souza P Evaluation of quality of life in patients with advanced renal cell carcinoma treated with temsirolimus vs interferon-alfa: results from a phase III randomized trial European Journal of Cancer Supplements, ECCO 15 Meeting Proceedings 2009 abstr 7134","DOI":"10.1016\/S1359-6349(09)71467-3"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2165\/11535290-000000000-00000","article-title":"Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma","volume":"28","author":"Zbrozek","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0072|cit72","unstructured":"see Hudes 2010"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0073|cit73","unstructured":"see Hudes 2010"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0074|cit74","unstructured":"see Hudes 2010"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0075|cit75","doi-asserted-by":"crossref","unstructured":"Jonasch E Corn P Asche RG Randomized phase II study of sorafenib with or without low-dose IFN in patients with metastatic renal cell carcinoma Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2007 abstr 5104","DOI":"10.1200\/jco.2007.25.18_suppl.5104"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/cncr.24685","article-title":"Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma","volume":"116","author":"Jonasch","year":"2010","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0077|cit77","doi-asserted-by":"crossref","unstructured":"Tannir NM Zurita AJ Heymach JV A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa: clinical results and biomarker analysis Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2008 abstr 5093","DOI":"10.1200\/jco.2008.26.15_suppl.5093"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1200\/JCO.2005.03.7309","article-title":"Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma","volume":"24","author":"Lee","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0079|cit79","doi-asserted-by":"crossref","unstructured":"Madhusudan S Protheroe A Vasey P A randomized phase II study of interferon alpha alone or in combination with thalidomide in metastatic renal cancer Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2004 abstr 4742","DOI":"10.1200\/jco.2004.22.90140.4742"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/annonc\/mdp067","article-title":"Patient-reported outcomes ina phase III, randomized study of sunitinib versus interferon-a as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population","volume":"20","author":"Castellano","year":"2009","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1200\/JOP.0922004","article-title":"Quality of life predicts progression-free survival in patients with renal cell carcinoma treated with sunitinib versus interferon alfa","volume":"5","author":"Cella","year":"2009","journal-title":"Journal of Oncology Practice"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.2007.13.5145","article-title":"Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial","volume":"26","author":"Cella","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0083|cit83","doi-asserted-by":"crossref","unstructured":"Cella D Li JZ Cappelleri JC Quality of life predicts for progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib compared to interferon-alpha Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2007 abstr 6594","DOI":"10.1200\/jco.2007.25.18_suppl.6594"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0084|cit84","doi-asserted-by":"crossref","unstructured":"Cella D Li JZ Cappelleri JC Quality of life predicts for progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib compared to interferon-alpha www.asco.org\/virtual meeting [accessed 10 January 2007] 2007","DOI":"10.1200\/jco.2007.25.18_suppl.6594"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/sj.bjc.6605552","article-title":"Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-a in a phase III trial: final results and geographical analysis","volume":"102","author":"Cella","year":"2010","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0086|cit86","doi-asserted-by":"crossref","unstructured":"Figin RA Hutson TE Tomczak P Overall survival with sunitinib versus interferon-alfa as first-line treatment of metastatic renal cell carcinoma Journal of Clinical Oncology, American Society of Clinical Oncology Annual Meeting Proceedings 2008 abstr 5024","DOI":"10.1200\/jco.2008.26.15_suppl.5024"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/cncr.23776","article-title":"Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma","volume":"11","author":"Motzer","year":"2008","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0088|cit88","doi-asserted-by":"crossref","unstructured":"Motzer RJ Figlin RA Hutson TE Sunitinib versus interferon-alfa as first-line treatment of metastatic renal cell carcinoma: updated results and analysis of prognostic factors Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2007 abstr 5024","DOI":"10.1200\/jco.2007.25.18_suppl.5024"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0089|cit89","doi-asserted-by":"crossref","unstructured":"Motzer RJ Figlin RA Hutson TE Sunitinib versus interferon-alfa as first-line treatment of metastatic renal cell carcinoma: updated results and analysis of prognostic factors www.asco.org\/virtual meeting [accessed 10 January 2007] 2007","DOI":"10.1200\/jco.2007.25.18_suppl.5024"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0091|cit91","doi-asserted-by":"crossref","unstructured":"Motzer RJ Hutson TE Tomczak P Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2006 abstr LBA3","DOI":"10.1200\/jco.2006.24.18_suppl.lba3"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0093|cit93","doi-asserted-by":"crossref","unstructured":"Motzer RJ Michaelson MD Hutson TE Sunitinib versus interferon-alfa as first-line treatment of metastatic renal cell carcinoma: updated efficacy and safety results and further analysis of prognostic factors European Journal of Cancer Supplements 2007 abstr 4509","DOI":"10.1016\/S1359-6349(07)71140-0"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0094|cit94","doi-asserted-by":"crossref","unstructured":"Patil S Figlin RA Hutson TE TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma patients treated in a phase III trial with sunitinib versus interferon-alfa Journal of Clinical Oncology, ASCO Annual Meeting proceedings 2010 abstr 4594","DOI":"10.1200\/jco.2010.28.15_suppl.4594"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0095|cit95","doi-asserted-by":"crossref","unstructured":"Wilkerson J Stein WD Kim ST Validation of kinetic analysis of renal cancer regression and growth following treatment with sunitinib and interferon-alfa: analysis of the pivotal randomized trial Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2010 abstr 4597","DOI":"10.1200\/jco.2010.28.15_suppl.4597"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0096|cit96","doi-asserted-by":"crossref","unstructured":"Beaumont J Cella D Hollaender N Results from additional analyses of patient reported outcomes in RECORD-1 - a randomized trial of everolimus with metastatic renal cell carcinoma patients European Journal of Cancer Supplements, ECCO 15 Meeting Proceedings 2009 abstr 7127","DOI":"10.1016\/S1359-6349(09)71460-0"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0097|cit97","doi-asserted-by":"crossref","unstructured":"Beaumont J Cella D Hutson T Patient-reported outcomes in a randomized trial of everolimus with metastatic renal cell carcinoma patients Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2009 abstr e17516","DOI":"10.1200\/jco.2009.27.15_suppl.e17516"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0098|cit98","unstructured":"Escudier B Ravaud A Oudard S Phase-3 randomized trial of everolimus (RAD001) vs placebo in metastatic renal cell carcinoma Annals of Oncology, ESMO Meeting Proceedings 2008 abstr 720"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0099|cit99","doi-asserted-by":"crossref","unstructured":"Hutson T Negrier S Kay A Randomized placebo-controlled, phase 3 study of everolimus, a novel therapy for patients with metastatic renal cell carcinoma: subgroup analysis of patients progressing on prior bevacizumab therapy European Journal of Cancer Supplements, ECCO 15 Meeting Proceedings 2009 abstr 7136","DOI":"10.1016\/S1359-6349(09)71469-7"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0100|cit100","unstructured":"Hutson TE Calvo E Escudier BJ Everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the RECORD-1 study Genitourinary Cancers Symposium Proceedings, American Society of Oncology 2010 abstr 362"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0101|cit101","doi-asserted-by":"crossref","unstructured":"Kay A Motzer R Figlin R Updated data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma Genitourinary Cancers Symposium Proceedings, American Society of Oncology 2009 abstr 278","DOI":"10.1016\/S1569-9056(09)60262-1"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0102|cit102","doi-asserted-by":"crossref","unstructured":"Korhonen P Haas T Zuber E Overall survival among metastatic renal cell carcinoma patients corrected for crossover using a rank preserving structural failure time model: analyses from the everolimus phase III trial European Journal of Cancer Supplements, ECCO 15 Meeting Proceedings 2009 abstr 7155","DOI":"10.1016\/S1359-6349(09)71488-0"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0103|cit103","doi-asserted-by":"crossref","unstructured":"Korhonen P Malangone E Sherman S Overall survival of metastatic renal cell carcinoma patients corrected for crossover using inverse probability of censoring wights and rank preserving structural failure time models: two analyses from the RECORD-1 trial Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2010 abstr 4595","DOI":"10.1200\/jco.2010.28.15_suppl.4595"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0105|cit105","doi-asserted-by":"crossref","unstructured":"Motzer RJ Escudier B Oudard S RAD001 vs placebo in patients with metastatic renal cell carcinoma after progression on VEGFr-TKI therapy: results from a randomized, double-blind, multicenter phase-III study Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2008 abstr LBA5026","DOI":"10.1200\/jco.2008.26.15_suppl.lba5026"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0106|cit106","doi-asserted-by":"crossref","unstructured":"Osanto S Hutson TE Calvo E Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2010 abstr 4608","DOI":"10.1200\/jco.2010.28.15_suppl.4608"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1164\/rccm.200911-1720OC","article-title":"Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma","volume":"182","author":"White","year":"2010","journal-title":"American Journal of Respirology and Critical Care Medicine"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0108|cit108","doi-asserted-by":"crossref","unstructured":"Wiederkehr D Howe CJ Casciano R Overall survival among metastatic renal cell carcinoma patients corrected for crossover using inverse probability of censoring weights: analyses from the everolimus phase III trial European Journal of Cancer Supplements, ECCO 15 Meeting Proceedings 2009 abstr 7131","DOI":"10.1016\/S1359-6349(09)71464-8"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0109|cit109","doi-asserted-by":"crossref","unstructured":"Zuber E Korhonen P Branson M Correcting overall survival effect for the impact of cross-over via rank preserving structural failure time model: case of mRCC RECORD-1 trial of everolimus Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2010 abstr 4690","DOI":"10.1200\/jco.2010.28.15_suppl.4690"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0110|cit110","doi-asserted-by":"crossref","unstructured":"Procopio G Verzoni E Bracarda S A randomized, prospective, phase 2 study, with sorafenib (So) and interleukin-2 versus So alone as first line treatment in advanced renal cell cancer: ROSORC trial European Journal of Cancer Supplements, ECCO 15 Meeting Proceedings 2009 abstr 7107","DOI":"10.1016\/S1359-6349(09)71440-5"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0111|cit111","doi-asserted-by":"crossref","unstructured":"Procopio G Verzoni E Bracarda S Subgroup analysis and updated results of the randomized study comparing sorafenib (So) plus interleukin-2 versus So alone as first-line treatment in metastatic renal cell carcinoma Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2010 abstr 4589","DOI":"10.1200\/jco.2010.28.15_suppl.4589"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0113|cit113","unstructured":"Hawkins RE Ravaud A von der Masse H Lapatinib extends survival in patients with high ErbB1 (EGFR) tumour expression: subgroup results of a phase III trial in advanced renal cell carcinoma Annals of Oncology, ESMO Meeting Proceedings 2006 abstr 440O"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0114|cit114","doi-asserted-by":"crossref","unstructured":"Ravaud A Gardner J Hawkins R Efficacy of lapatinib in patients with high tumor EGFR expression: results of a phase III trial in advanced renal cell carcinoma Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2006 abstr 4502","DOI":"10.1200\/jco.2006.24.18_suppl.4502"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0115|cit115","doi-asserted-by":"crossref","unstructured":"Ravaud A Gardner J Hawkins R Efficacy of lapatinib in patients with high tumor EGFR expression: results of a phase III trial in advanced renal cell carcinoma www.asco.org\/virtual meeting [accessed 10 January 2007] 2006","DOI":"10.1200\/jco.2006.24.18_suppl.4502"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1200\/JCO.2007.14.5029","article-title":"Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial","volume":"26","author":"Ravaud","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0117|cit117","doi-asserted-by":"crossref","unstructured":"Halabi S Rini BI Stadler WM Small EJ Use of progression-free survival to predict overall survival in patients with metastatic renal cell carcinoma Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2010 abstr 4525","DOI":"10.1200\/jco.2010.28.15_suppl.4525"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0118|cit118","unstructured":"Harzstark AL Halabi S Stadler WM Hypertension is associated with clinical outcome for patients with metastatic renal cell carcinoma treated with interferon and bevacizumab on CALGB 90206 Genitourinary Cancers Symposium, American Society of Clinical Oncology 2010 abstr 351"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0119|cit119","doi-asserted-by":"crossref","unstructured":"Rini BI Halabi S Rosenberg J Bevacizumab plus interferon-alfa versus interferon-alfa monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206 Journal of Clinical Oncology, 2009 American Society of Clinical Oncology Annual Meeting Proceedings 2009 abstr LBA5019","DOI":"10.1200\/jco.2009.27.15_suppl.lba5019"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","article-title":"Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206","volume":"26","author":"Rini","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0121|cit121","doi-asserted-by":"crossref","unstructured":"Rini BI Halabi S Rosenberg JE CALGB 90206: a phase III trial of bevacizumab plus interferon-alfa versus interferon-alfa monotherapy in metastatic renal cell carcinoma Genitourinary Cancers Symposium, American Society of Clinical Oncology 2008 abstr 350","DOI":"10.1200\/JCO.2008.16.9847"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1158\/1078-0432.CCR-03-0605","article-title":"Cancer and Leukemia Group B 90206: a randomized phase III trial of interferon-a or interferon-a plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma","volume":"10","author":"Rini","year":"2004","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1464-410X.2005.05680.x","article-title":"A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma","volume":"96","author":"Srinivas","year":"2005","journal-title":"BJU International"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.44.150","article-title":"Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma -CALGB 69901","volume":"23","author":"Stadler","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3816\/CGC.2006.n.011","article-title":"A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma","volume":"4","author":"Hutson","year":"2006","journal-title":"Clinical Genitourinary Cancer"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0126|cit126","doi-asserted-by":"crossref","unstructured":"Hutson TE Davis ID Machiels JP Pazopanib (GW786034) is active in metastatic renal cell carcinoma: interim results of a phase II randomized discontinuation trial Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2007 abstr 5031","DOI":"10.1200\/jco.2007.25.18_suppl.5031"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0127|cit127","doi-asserted-by":"crossref","unstructured":"Hutson TE Davis ID Machiels JP Pazopanib (GW786034) is active in metastatic renal cell carcinoma: interim results of a phase II randomized discontinuation trial www.asco.org\/virtual meeting [accessed 10 January 2007] 2007","DOI":"10.1200\/jco.2007.25.18_suppl.5031"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0129|cit129","doi-asserted-by":"crossref","unstructured":"Sternberg CN Szczylik C Lee E A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2009 abstr 5021","DOI":"10.1200\/jco.2009.27.15_suppl.5021"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00002371-200407000-00001","article-title":"A pilot study of anti-angiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma","volume":"27","author":"Elaraj","year":"2004","journal-title":"Journal of Immunotherapy"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0132|cit132","unstructured":"Yang JC Haworth L Steinberg S Rosenberg SA Novotny W A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2002 abstr 15"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0133|cit133","doi-asserted-by":"crossref","unstructured":"see Yang 2003","DOI":"10.2307\/25563999"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0134|cit134","doi-asserted-by":"crossref","unstructured":"see Yang 2003","DOI":"10.2307\/25563999"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0135|cit135","doi-asserted-by":"crossref","unstructured":"see Yang 2003","DOI":"10.2307\/25563999"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1200\/JCO.2008.20.5476","article-title":"Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma","volume":"27","author":"Escudier","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0137|cit137","doi-asserted-by":"crossref","unstructured":"Escudier B Srinivas S Roigas J A phase II study of continuous daily administration of sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma - final results European Journal of Cancer Supplements, ECCO 14 Meeting Proceedings 2007 abstr 4504","DOI":"10.1016\/S1359-6349(07)71135-7"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0138|cit138","first-page":"abstr 5040","article-title":"Continuous daily administration of sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma","volume":"25 suppl","author":"Srinivas","year":"2007","journal-title":"Journal of Clinical Oncology, ASCO Annual Meeting Proceedings"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.1200\/JCO.2005.23.648","article-title":"Intracellular signal transduction pathway proteins as targets for cancer therapy","volume":"23","author":"Adjei","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0140|cit140","doi-asserted-by":"crossref","unstructured":"Amato RJ Harris P Dalton M A phase II trial of intra-patient dose-escalated sorafenib in patients with metastatic renal cell cancer Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2007 abstr 5026","DOI":"10.1200\/jco.2007.25.18_suppl.5026"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0141|cit141","doi-asserted-by":"crossref","unstructured":"Amato RJ Harris P Dalton M A phase II trial of intra-patient dose-escalated sorafenib in patients with metastatic renal cell cancer www.asco.org\/virtual meeting [accessed 10 January 2007] 2007","DOI":"10.1200\/jco.2007.25.18_suppl.5026"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1200\/JCO.2009.24.9730","article-title":"Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study","volume":"28","author":"Antoun","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2005.03.6913","article-title":"When does the presence of the target predict response to the targeted agent?","volume":"24","author":"Bergsland","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/01.coc.0000258732.80710.05","article-title":"Effects of sorafenib on symptoms and quality of life. Results from a large randomized placebo-controlled study in renal cancer","volume":"30","author":"Bukowski","year":"2007","journal-title":"American Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","article-title":"Sunitinib: from rational design to clinical efficacy","volume":"25","author":"Chow","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD006017.pub2-BIB0146|cit146","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001425.pub2","article-title":"Immunotherapy for advanced renal cell cancer","author":"Coppin","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0147|cit147","first-page":"1","article-title":"Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and\/or sorafenib","volume":"4","author":"Coppin","year":"2010","journal-title":"Biologics: Targets and Therapy"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0149|cit149","doi-asserted-by":"crossref","unstructured":"Dutcher JP Szczylik C Tannir N Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon-alpha www.asco.org\/virtual meeting [accessed 10 January 2007] 2007 abstract A5033","DOI":"10.1200\/jco.2007.25.18_suppl.5033"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12032-009-9177-0","article-title":"Effect of temsirolimus versus interferon-\u03b1 on outcome of patients with advanced renal cell carcinoma of different tumor histologies","volume":"26","author":"Dutcher","year":"2009","journal-title":"Medical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/jnci\/djn319","article-title":"Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial","volume":"100","author":"Eisen","year":"2008","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","article-title":"Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial","volume":"27","author":"Escudier","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1470-2045(09)70380-8","article-title":"Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new","volume":"11","author":"Furge","year":"2010","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJM199804303381804","article-title":"Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma","volume":"338","author":"Gleave","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1158\/1078-0432.CCR-05-0130","article-title":"Objective responses in patients with malignant melanoma or renal cell cancer in early studies do not predict regulatory approval","volume":"11","author":"Goffin","year":"2005","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","article-title":"Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial","volume":"10","author":"Gore","year":"2009","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0157|cit157","unstructured":"GRADEpro"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11523-010-0144-7","article-title":"Emerging molecular classification in renal cell carcinoma: implications for drug development","volume":"5","author":"Hacker","year":"2010","journal-title":"Targeted Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0159|cit159","first-page":"2882","article-title":"Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy","volume":"9","author":"Harding","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0162|cit162","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008 Available from www.cochrane-handbook.org [accessed 24 November 2010]","DOI":"10.1002\/9780470712184"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","article-title":"Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis","volume":"66","author":"Houk","year":"2010","journal-title":"Cancer Chemotherapy Pharmacology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0164|cit164","doi-asserted-by":"crossref","unstructured":"Hutson TE Davis ID Machiels JP Pazopanib (GW786034) is active in metastatic renal cell carcinoma: interim results of a phase II randomized discontinuation trial Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2007 abstr 5031","DOI":"10.1200\/jco.2007.25.18_suppl.5031"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ccr.2008.11.005","article-title":"Kidney cancer: now available in a new flavor","volume":"14","author":"Kaelin","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1097\/01.ju.0000177487.64651.3a","article-title":"A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials","volume":"174","author":"Leibovich","year":"2005","journal-title":"Journal of Urology"},{"issue":"S2","key":"10.1002\/14651858.CD006017.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1464-410X.2005.05189.x","article-title":"The genetic basis of cancer of the kidney: implications for gene-specific management","volume":"95","author":"Linehan","year":"2005","journal-title":"BJU International"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0168|cit168","unstructured":"Massard C Zonierek J Laplanche A Incidence of brain metastasis in advanced renal cell carcinoma among patients randomized in a phase III trial of sorafenib, an oral multi-kinase inhibitor Annals of Oncology, ESMO Meeting Proceedings 2006 abstr 454P"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.2005.03.206","article-title":"Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma","volume":"23","author":"McDermott","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1200\/JCO.2005.05.179","article-title":"Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma","volume":"23","author":"Mekhail","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0171|cit171","doi-asserted-by":"crossref","unstructured":"Merchan JR G. Liu T. Fitch Phase I\/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2007 abstr 5034","DOI":"10.1200\/jco.2007.25.18_suppl.5034"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0302-2838(03)00105-2","article-title":"Rational selection of a control arm for randomized trials in metastatic renal cell carcinoma","volume":"43","author":"Mickisch","year":"2003","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-9-34","article-title":"Metastatic renal cell cancer treatments: an indirect comparison meta-analysis","volume":"9","author":"Mills","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2004.06.132","article-title":"Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma","volume":"22","author":"Motzer","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00345-004-0467-z","article-title":"Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie","volume":"23","author":"Negrier","year":"2005","journal-title":"World Journal of Urology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0180|cit180","first-page":"300","article-title":"Guidance on cancer services: improving outcomes in urological cancers - the research evidence","volume-title":"National Institute for Clinical Excellence, UK","author":"Mason","year":"2002"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/sj.bjc.6605446","article-title":"SUN vs BEV + IFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival","volume":"102","author":"Nuijten","year":"2010","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1464-410X.1989.tb05147.x","article-title":"Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma","volume":"63","author":"Oliver","year":"1989","journal-title":"British Journal of Urology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s11523-010-0145-6","article-title":"Targeted therapies for renal cell carcinoma: understanding their impact on survival","volume":"5","author":"Pal","year":"2010","journal-title":"Targeted Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/cncr.24713","article-title":"Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients","volume":"116","author":"Patil","year":"2010","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1200\/JCO.2005.01.186","article-title":"Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma","volume":"23","author":"Rini","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1200\/JCO.2008.21.7034","article-title":"Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma","volume":"27","author":"Rini","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1158\/1078-0432.CCR-09-2273","article-title":"New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance","volume":"16","author":"Rini","year":"2010","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1200\/JCO.2003.01.204","article-title":"The phase III trial in the era of targeted therapy: unravelling the \"go or no go\" decision","volume":"21","author":"Roberts","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nature03095","article-title":"Targeted cancer therapy","volume":"432","author":"Sawyers","year":"2004","journal-title":"Nature"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2005.04.2408","article-title":"New targets, therapies, and toxicities: lessons to be learned","volume":"24","author":"Stadler","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/cncr.24864","article-title":"Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America","volume":"116","author":"Stadler","year":"2010","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1200\/JCO.2007.14.1127","article-title":"Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and pharmacokinetic and pharmacodynamic data","volume":"26","author":"Tanaka","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/sj.bjc.6605167","article-title":"Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness","volume":"101","author":"Thompson Coon","year":"2009","journal-title":"British Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD006017.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta14020","article-title":"Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation","volume":"14","author":"Thompson Coon","year":"2010","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/sj.bjc.6605447","article-title":"Reply: SUN vs BEV\/IFN in first-line mRCC therapy","volume":"102","author":"Thompson Coon","year":"2010","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0094-0143(03)00021-1","article-title":"The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician","volume":"30","author":"Uzzo","year":"2003","journal-title":"Urologic Clinics of North America"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"7582","DOI":"10.1158\/1078-0432.CCR-09-2131","article-title":"Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma","volume":"15","author":"Young","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD006017.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2165\/11535290-000000000-00000","article-title":"Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma","volume":"28","author":"Zbrozek","year":"2010","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1002\/14651858.CD006017.pub2-BIB0201|cit201","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006017.pub2","article-title":"Targeted therapy for advanced renal cell carcinoma","author":"Coppin","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006017.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,25]],"date-time":"2024-02-25T09:23:52Z","timestamp":1708853032000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006017.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Urology Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2008,4,23]]},"references-count":201,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2011,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006017.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,23]]}}}